| 263 / Vnitř Lék. 2024;70(4):260-263 / VNITŘNÍ LÉKAŘSTVÍ www.casopisvnitrnilekarstvi.cz CO JE NOVÉHO V… Novinky v geriatrii – co je nového u demencí? LITERATURA 1. World Health Organization. Dementia fact sheet. 2023. Availabler from: https://www. who.int/news-room/fact-sheets/detail/dementia 2. Vaňková H, Hrnčiariková D, Závadová I, et al. Mezioborová klinická doporučení pro diagnostiku a léčbu Alzheimerovy nemoci: „Bílá kniha paliativní péče“ v aktuálním kontextu. Geri a gero. 2024;(1):47-51. 3. Doporučené diagnostické a terapeutické postupy pro všeobecné praktické lékaře. Demence Novelizace 2024. Availabler from: http://svl.cz/doporucene-postupy/demence-100017 4. Kleinová L, Cerman J, Hlávka J, et al. Nové farmakologické možnosti v léčbě Alzheimerovy nemoci. Cesk Slov Neurol N. 2022;85(6):462-469. 5. Hoy SM. Lecanemab: First approval. Drugs. 2023;83(4):359–365. doi: 10.1007/s40265023-01851-2. 6. Nelson S, Lopez O. Lecanemab for Alzheimer disease. Neurology. 2024; 102 (7). e209265. doi: 10.1212/WNL.0000000000209265. 7. Lapka M. Lecanemab. Remedia. 2023;33:73-76. 8. Eisai global. New release. March 22, 2024. Availabler from: https://www.eisai.com/ news/2024/news202417.html 9. van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer’s Disease. N Engl J Med. 2023;388(1):9-21. doi: 10.1056/NEJMoa2212948. 10. Gueorguieva I, Willis BA, Chua L, et al. Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer’s Disease. Clin Pharmacol Ther. 2023; 113(6):1258-1267. doi: 10.1002/cpt.2875. 11. Lo A C, Duggan EC, Wessels AM, et al. Donanemab in early Alzheimer’s disease. N Engl J Med. 2021;384(18):1691-1704. 12. The New York Times. March 8,2024. Availabler from: https://www.nytimes. com/2024/03/08/health/alzheimers-drug-donanemab.html 13. Qiao Y, Gu J, Yu M, et al. Comparative Efficacy and Safety of Monoclonal Antibodies for Cognitive Decline in Patients with Alzheimer’s Disease: A Systematic Review and Network Meta-Analysis. CNS Drugs. 2024 Mar;38(3):169-192. doi: 10.1007/s40263-024-01067-2. 14. Ross EL, Weinberg MS, Arnold SE. Cost-effectiveness of aducanumab and donanemab for early Alzheimer disease in the US. JAMA Neurol. 2022;79(5):478-487. doi: 10.1001/ jamaneurol.2022.0315. 15. Nguyen HV, Mital S, Knopman DS, Alexander GC. Cost-effectiveness of lecanemab for individuals with early-stage Alzheimer disease. Neurology. 2024;102:e209218. doi: 10.1212/ WNL.0000000000209218. 16. Lu X, Liu C, Shao F. Phototherapy improves cognitive function in dementia: A systematic review and meta-analysis. Brain Behav. 2023 May;13(5):e2952. doi: 10.1002/brb3.2952. 17. Creavin ST, Wisniewski S, Noel-Storr AH, et al. Mini-Mental State Examination (MMSE) for the detection of dementia in clinically unevaluated people aged 65 and over in community and primary care populations. Cochrane Database Syst Rev. 2016 Jan 13;2016(1):CD011145. doi: 10.1002/14651858.CD011145. 18. Tao T, Feng G, Fang Y. Association between aspirin use and risk of dementia: a systematic review and meta-analysis. Eur Geriatr Med. 2024;15(1):3-18. doi: 10.1007/s41999023-00877-9. 19. Xu M, Zhu Y, Chen J et al. Effects of folic acid supplementation on cognitive impairment: A meta-analysis of randomized controlled trials. J Evid Based Med. 2024;17(1):134144. doi: 10.1111/jebm.12588. 20. Akhgarjand C, Vahabi Z, Shab-Bidar S, et al. The effects of probiotic supplements on oxidative stress and inflammation in subjects with mild and moderate Alzheimer’s disease: a randomized, double-blind, placebo-controlled study. Inflammopharmacology. 2024;32(2):1413-1420. doi: 10.1007/s10787-023-01427-2. Pro věrné čtenáře Součástí Vnitřního lékařství 4/2024 je navíc suppelementum Zaznělo na 2. diabetologii pro praxi v Olomouci. Pokud se chcete o 2. diabetologii pro praxi dozvědět více, na www.diabetologiepropraxi.cz/archiv najdete tiskovou zprávu a také malou fotogalerii z této vzdělávací akce.
RkJQdWJsaXNoZXIy NDA4Mjc=